ModerateSecond-generation antihistamine×Mineral supplements. Macrominerals
Updated · Methodology
Mechanism
Fexofenadine is barely metabolised, in the liver or elsewhere. It is eliminated mainly in bile, with up to 10% of the dose excreted unchanged in urine, and its half-life is 11–15 hours (fexofenadine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Its exposure is changed by P-gp inhibitors or inducers such as erythromycin and ketoconazole (fexofenadine SmPC, AEMPS, section 4.5). An antacid containing aluminium and magnesium hydroxide gels taken 15 minutes before fexofenadine reduced its bioavailability through binding in the gastrointestinal tract (fexofenadine SmPC, AEMPS, section 4.5). Magnesium salts used for magnesium deficiency also bind several drugs in the gut: tetracyclines, quinolones and bisphosphonates. Fexofenadine is not among them, and the SmPCs of these salts do not describe them as antacids (Magnesioboi SmPC, AEMPS, section 4.5).
Symptoms
The documents describe no symptoms specific to the combination: when fexofenadine binds to an antacid, less of it is absorbed and its antiallergic effect may be weaker (fexofenadine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Common adverse effects of fexofenadine are headache, somnolence, dizziness and nausea (fexofenadine SmPC, AEMPS, section 4.8). Magnesium taken on an empty stomach can cause diarrhoea, and in renal impairment it can cause hypermagnesaemia (Magnesioboi SmPC, AEMPS, section 4.4).
Management
If magnesium is taken as an antacid containing magnesium hydroxide (often together with aluminium hydroxide), a 2-hour interval is left between it and fexofenadine (fexofenadine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). For magnesium salts taken for magnesium deficiency, the documents require no such interval: fexofenadine is not among the drugs that have to be spaced from them (Magnesioboi SmPC, AEMPS, section 4.5). With prolonged magnesium use, blood magnesium and calcium are monitored, and in renal impairment the magnesium dose is adjusted (Magnesioboi SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Lactato de magnesio, Magnesioboi 48,62 mg comprimidos (nº registro 54347), sección 4.5 (2025)– AEMPS, CIMA, nº registro 54347 (Magnesioboi 48,62 mg comprimidos, Laboratorios Cinfa), revisión 07/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Fexofenadina, Fexofenadina Opella 180 mg (nº registro 61911), sección 4.5 (2026)– AEMPS, CIMA, nº registro 61911 (Fexofenadina Opella 180 mg comprimidos recubiertos con película, Opella Healthcare Spain), revisión 04/2026, secciones 4.4, 4.5, 4.7, 4.8, 5.1 y 5.2